Moscow, August 22
A COVID-19 vaccine developed by Russia’s Vector State Research Center of Virology and Biotechnology seems to be secure in early checks in people, the media has reported.
This vaccine, totally different from the one dubbed “Sputnik V” which has already been accredited by the nation, produced no uncomfortable side effects within the volunteers who acquired the primary shot of the vaccine, Russia’s Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing mentioned on Friday.
The company mentioned medical trials of the “EpiVacCorona” vaccine can be accomplished in September.
“All inoculated volunteers are feeling well. To date, the first vaccination was administered to 57 volunteers, while 43 received placebo,” the company mentioned in a press release, including that no uncomfortable side effects had been noticed within the volunteers who acquired the vaccine.
According to a report in TASS information company, which quoted the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, the vaccine elicits an immune response after double administration with the interval of 14 to 21 days.
So far, only one volunteer had been inoculated twice, mentioned the report.
Earlier this month, Russia registered the “Sputnik V”, turning into the primary nation to approve a COVID-19 vaccine.
Media stories this week mentioned Russia was now planning a large-scale trial of its “Sputnik V” vaccine involving 40,000 individuals. IANS